title: Norepinephrine-induced plasma dopamine decrease in man: pharmacological evidence of the involvement of alpha 2-adrenoceptors.
abstract: OBJECTIVE
  The purposes of this study were: (1) to test whether intravenous infusion of norepinephrine can affect plasma dopamine levels; and (2) to explore to what extent dopamine-2 or alpha 2-receptors play a role in this response.
  
  
  METHODS
  Norepinephrine infusion in man was performed to test whether the increase in norepinephrine during sympathetic stimulation can affect dopamine release. Specific antagonists of presynaptic dopamine-2 and alpha 2-receptors were administered to test the receptor(s) involved in this possible regulatory phenomenon.
  
  
  METHODS
  Plasma catecholamine levels were investigated in seven normal subjects before and after administration of domperidone (dopamine-2 antagonist), yohimbine (alpha 2-antagonist) and norepinephrine.
  
  
  RESULTS
  Both oral domperidone and yohimbine induced a significant increase in both plasma norepinephrine and plasma dopamine. Norepinephrine infusion induced a significant decrease in plasma dopamine. Pretreatment with domperidone only partially counteracted this inhibitory effect of norepinephrine infusion, whereas yohimbine fully counteracted it.
  
  
  CONCLUSIONS
  Our data show that norepinephrine may act as a hormone at plasma concentrations as low as 450 pg/ml. The norepinephrine-induced plasma dopamine decrease seems to be alpha 2-adrenoceptor-mediated. This norepinephrine effect may be involved in the physiologic decrease in plasma dopamine that we demonstrated in the upright position in normal subjects.
authors.affiliation: Department of Internal Medicine, University of Genoa, Italy.
authors.forename: N R
authors.initials: NR
authors.lastname: Musso
authors.forename: R
authors.initials: R
authors.lastname: Gianrossi
authors.forename: C
authors.initials: C
authors.lastname: Vergassola
authors.forename: A
authors.initials: A
authors.lastname: Pende
authors.forename: A
authors.initials: A
authors.lastname: Ioverno
authors.forename: G
authors.initials: G
authors.lastname: Galbariggi
authors.forename: G
authors.initials: G
authors.lastname: Lotti
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004294:Domperidone / Q000494:pharmacology; D004298:Dopamine / Q000097:blood*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009638:Norepinephrine / Q000097:blood / Q000494:pharmacology*; D011897:Random Allocation; D011942:Receptors, Adrenergic, alpha / Q000502:physiology*; D012016:Reference Values; D016683:Supine Position; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D011942:Receptors, Adrenergic, alpha; D015016:Yohimbine; D004294:Domperidone; D004298:Dopamine; D009638:Norepinephrine